We are the seed accelerator of Charleroi Brussels South Biopark
Bone Therapeutics SA announces that it has successfully raised EUR 8.5 million in gross proceeds through a private placement. Thomas Lienard, Chief Executive Officer, commented: “The level of support we received from our existing and new investors is a true recognition of our potential to fundamentally change the way patients with bone diseases and orthopaedic conditions are treated".
Please discover the press release here.
Univercells announces that it has been awarded a $14.3 million grant by the Bill & Melinda Gates Foundation to increase the availability of measles and rubella (M&R) vaccines in low- and middle-income countries (LMICs). Univercells will adapt the process design of its proprietary NevoLine™ platform to deliver affordable M&R vaccines. Please discover the press release here.